Merck, DCAS9P300-1EA, Sigma CRISPR dCas9-p300 Activator Expression Plasmid

General description
A gene activation system based on a fusion of inactive Cas9 or dCas9 to the catalytic histone acetyltransferase (HAT) core domain of the human E1A-associated protein p300. The dCas9-p300 CRISPR Gene Activator with the p300 domain represents a distinct mechanism of action relative to dCas9-VP64 or other similar gene activation motifs. The p300 histone acetyltransferase protein opens a transcriptional highway by releasing the DNA from its heterochromatin state and allowing for continued and robust gene expression by the endogenous cellular machinery. The Cas9 expression plasmids use the CMV promoter for strong transient expression of Cas9. Alternate promoters can be substituted by replacement of CMV using MluI and NheI. Also, the Cas9 expression plasmids can be linearized using XbaI for T7-based mRNA production.
Application
Functional Genomics/Target ValidationEpigenetic Modification
Transcriptional Activation

Features and Benefits
The Sigma CRISPR dCas9p300 plasmid co-expresses p300-HAT and GFP, to easily monitor delivery and expression in your target cell type (figure 1)gRNAs can successfully direct nuclease-deficient Cas9 (dCas9) fused to p300 HAT catalytic domain to increase levels of histone acetylation and endogenous gene expressionThe dCas9-p300 histone acetylation approach represents a distinct mechanism of action relative to dCas9-VP64 or other similar gene activation motifs

Other Notes
1 vial containing 1ug of dCas9-p300 plasmid.
Must be used with U6-gRNA only expressing plasmid.
To order U6-gRNA plasmids, please visit sigma.com/crisprs

Click here for more information on dcas9-p300 Gene Activator Expression Plasmid.